Understanding The Role of Ubiquitin-Conjugating Enzyme E2 G2 in Cellular Processes

Target Name: UBE2G2

NCBI ID: G7327

UBE2G2

Understanding The Role of Ubiquitin-Conjugating Enzyme E2 G2 in Cellular Processes

Ubiquitin-conjugating enzyme E2 G2 (isoform 1) is a protein that plays a crucial role in the regulation of protein degradation in the cell. It is a member of the superfamily of ubiquitin enzymes, which are involved in the turnover of a wide variety of cellular proteins. UBE2G2 is widely expressed in many tissues and cells, including the liver, muscle, and brain. It is also highly conserved, with significant sequence identity across different species.

UBE2G2 is a cytoplasmic protein that is primarily localized to the endoplasmic reticulum (ER) and the cytoplasm. It is involved in the formation of ubiquitin chains, which are attached to target proteins and play a central role in protein degradation. UBE2G2 is a critical enzyme in the degradation of many protein substrates, including cytoskeletal components, transcription factors, and signaling proteins.

In addition to its role in protein degradation, UBE2G2 is also involved in the regulation of cellular processes such as cell growth, apoptosis, and autophagy. It is a negative regulator of the degradation of the protein known as p21, which is a hallmark of the T-cell Checkpoint pathway. UBE2G2 has also been shown to play a role in the regulation of mitochondrial function and metabolism.

Due to its involvement in multiple cellular processes, UBE2G2 has been identified as a potential drug target or biomarker. Studies have shown that inhibiting UBE2G2 can lead to the accumulation of damaged proteins, including those that are misfolded or have incorrect post-translational modifications. This accumulation of damaged proteins can lead to a range of cellular dysfunction, including the development of neurodegenerative diseases, cancer, and aging.

In addition to its potential as a drug target, UBE2G2 is also a promising biomarker for a variety of diseases. For example, increased levels of UBE2G2 have been detected in the brains of individuals with Alzheimer's disease, suggesting that it may be a useful diagnostic or therapeutic target in this disease. Similarly, high levels of UBE2G2 have also been observed in the livers of individuals with cancer, which may indicate the potential for targeting this enzyme as a therapy for cancer.

Another promising application of UBE2G2 is its potential as a therapeutic target for a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Research has shown that UBE2G2 is involved in the degradation of the neurotransmitter acetylcholine, which is a critical molecule involved in the development of neurodegenerative diseases. By inhibiting UBE2G2, researchers may be able to increase the levels of acetylcholine and potentially slow the progression of these diseases.

In conclusion, Ubiquitin-conjugating enzyme E2 G2 (isoform 1) is a protein that plays a crucial role in the regulation of protein degradation in the cell. It is a potential drug target or biomarker, and its involvement in cellular processes such as cell growth, apoptosis, and autophagy makes it an attractive target for researchers. Further studies are needed to fully understand the role of UBE2G2 in these processes and its potential as a therapeutic target.

Protein Name: Ubiquitin Conjugating Enzyme E2 G2

Functions: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins (PubMed:20061386). In vitro catalyzes 'Lys-48'-linked polyubiquitination (PubMed:20061386). Involved in endoplasmic reticulum-associated degradation (ERAD) (PubMed:22607976). Required for sterol-induced ubiquitination of 3-hydroxy-3-methylglutaryl coenzyme A reductase and its subsequent proteasomal degradation (PubMed:23223569)

The "UBE2G2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2G2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets